Tyra Biosciences Stock Has a Data Question Investors Can’t Ignore
Tyra Biosciences shares traded at $33.02 ahead of Friday’s Nasdaq session, below their 52-week high of $40.65. The company reported $383.5 million in cash at March 31 and a first-quarter net loss of $39.3 million. Three Phase 2 trials of dabogratinib are underway or planned, with initial bladder-cancer data expected in August. Wolfe Research initiated coverage this week, citing potential peak sales of $300–400 million.
